CY1105814T1 - Δαριφενακινη για χρηση στη θεραπεια της επειξης προς ουρηση λογω υπepλειτουργικης ουροδοχου κυστης - Google Patents

Δαριφενακινη για χρηση στη θεραπεια της επειξης προς ουρηση λογω υπepλειτουργικης ουροδοχου κυστης

Info

Publication number
CY1105814T1
CY1105814T1 CY20061101729T CY061101729T CY1105814T1 CY 1105814 T1 CY1105814 T1 CY 1105814T1 CY 20061101729 T CY20061101729 T CY 20061101729T CY 061101729 T CY061101729 T CY 061101729T CY 1105814 T1 CY1105814 T1 CY 1105814T1
Authority
CY
Cyprus
Prior art keywords
urine
suboperative
darifenakin
treatment
urinary bladder
Prior art date
Application number
CY20061101729T
Other languages
Greek (el)
English (en)
Inventor
Enrico Colli
Paul Quinn
Dzelal Serdarevic
Laurence Howard Skillern
Original Assignee
Novartis International Pharmaceutical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105814(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis International Pharmaceutical Ltd. filed Critical Novartis International Pharmaceutical Ltd.
Publication of CY1105814T1 publication Critical patent/CY1105814T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Inorganic Insulating Materials (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Document Processing Apparatus (AREA)
  • Processing Of Meat And Fish (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CY20061101729T 2001-12-14 2006-11-30 Δαριφενακινη για χρηση στη θεραπεια της επειξης προς ουρηση λογω υπepλειτουργικης ουροδοχου κυστης CY1105814T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (1)

Publication Number Publication Date
CY1105814T1 true CY1105814T1 (el) 2011-02-02

Family

ID=9927643

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101729T CY1105814T1 (el) 2001-12-14 2006-11-30 Δαριφενακινη για χρηση στη θεραπεια της επειξης προς ουρηση λογω υπepλειτουργικης ουροδοχου κυστης

Country Status (27)

Country Link
US (3) US20030130338A1 (cg-RX-API-DMAC7.html)
EP (1) EP1458376B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005516925A (cg-RX-API-DMAC7.html)
KR (1) KR100889086B1 (cg-RX-API-DMAC7.html)
CN (1) CN100488505C (cg-RX-API-DMAC7.html)
AT (1) ATE341323T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002236141B2 (cg-RX-API-DMAC7.html)
BR (1) BR0214925A (cg-RX-API-DMAC7.html)
CA (1) CA2469702C (cg-RX-API-DMAC7.html)
CY (1) CY1105814T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301283B6 (cg-RX-API-DMAC7.html)
DE (1) DE60215219T2 (cg-RX-API-DMAC7.html)
DK (1) DK1458376T3 (cg-RX-API-DMAC7.html)
ES (1) ES2276910T3 (cg-RX-API-DMAC7.html)
GB (1) GB0129962D0 (cg-RX-API-DMAC7.html)
HU (1) HU229908B1 (cg-RX-API-DMAC7.html)
IL (2) IL162391A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04005760A (cg-RX-API-DMAC7.html)
NO (1) NO20042586L (cg-RX-API-DMAC7.html)
NZ (1) NZ533421A (cg-RX-API-DMAC7.html)
PL (1) PL206034B1 (cg-RX-API-DMAC7.html)
PT (1) PT1458376E (cg-RX-API-DMAC7.html)
RU (1) RU2321398C2 (cg-RX-API-DMAC7.html)
SI (1) SI1458376T1 (cg-RX-API-DMAC7.html)
SK (1) SK287510B6 (cg-RX-API-DMAC7.html)
WO (1) WO2003051354A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200404289B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
AU2010211725C1 (en) * 2009-02-04 2014-10-16 Astellas Pharma Inc. Pharmaceutical composition for oral administration
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US20090162433A1 (en) 2009-06-25
DK1458376T3 (da) 2007-02-12
SI1458376T1 (sl) 2007-06-30
PT1458376E (pt) 2007-01-31
NO20042586L (no) 2004-06-18
AU2002236141A1 (en) 2003-06-30
CA2469702A1 (en) 2003-06-26
IL162391A0 (en) 2005-11-20
MXPA04005760A (es) 2005-03-31
KR100889086B1 (ko) 2009-03-16
GB0129962D0 (en) 2002-02-06
IL162391A (en) 2012-04-30
HUP0402625A2 (hu) 2005-04-28
CA2469702C (en) 2010-07-06
CN1604777A (zh) 2005-04-06
US8748476B2 (en) 2014-06-10
DE60215219T2 (de) 2007-10-18
ES2276910T3 (es) 2007-07-01
JP2013199506A (ja) 2013-10-03
RU2321398C2 (ru) 2008-04-10
NZ533421A (en) 2007-02-23
WO2003051354A1 (en) 2003-06-26
ZA200404289B (en) 2005-09-28
EP1458376A1 (en) 2004-09-22
JP2005516925A (ja) 2005-06-09
HK1073779A1 (zh) 2005-10-21
HU229908B1 (hu) 2014-12-29
CZ301283B6 (cs) 2009-12-30
CZ2004719A3 (cs) 2005-01-12
US20030130338A1 (en) 2003-07-10
SK287510B6 (sk) 2010-12-07
DE60215219D1 (de) 2006-11-16
RU2004121780A (ru) 2005-08-10
SK2502004A3 (en) 2004-10-05
AU2002236141B2 (en) 2007-02-01
BR0214925A (pt) 2004-12-21
US20070264333A1 (en) 2007-11-15
CN100488505C (zh) 2009-05-20
ATE341323T1 (de) 2006-10-15
KR20040066892A (ko) 2004-07-27
PL206034B1 (pl) 2010-06-30
EP1458376B1 (en) 2006-10-04
PL369426A1 (en) 2005-04-18
JP2010024244A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
DK1404331T3 (da) Sustained release-formuleringer af oxymorphon
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
CY1112395T1 (el) Δισκιο βαλσαρτανης
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
DK1339407T3 (da) Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
DK0998287T3 (da) Anvendelse af levobupivacain
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
HRP20050439B1 (hr) Nova upotreba dekstran sulfata
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
DK1150704T3 (da) Melagatran til behandling af betændelse
UY28017A1 (es) Tratamiento terapéutico
EP1594435A4 (en) INHIBITION OF HIV-1 REPLICATION BY TREATMENT OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DK1458376T3 (da) Darifenacin til anvendelse i behandlingen af imperiös vandladningstrang fremkaldt af overaktiv urinblære
DK1315496T3 (da) Behandling af inflammatoriske lidelser
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20034357D0 (no) Terapeutisk middel for bl¶reirriterende symptomer forbundet med benign prostatahyperplasi
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου